UK markets close in 8 hours 17 minutes
  • FTSE 100

    7,217.53
    0.00 (0.00%)
     
  • FTSE 250

    23,054.09
    0.00 (0.00%)
     
  • AIM

    1,239.90
    0.00 (0.00%)
     
  • GBP/EUR

    1.1844
    -0.0008 (-0.06%)
     
  • GBP/USD

    1.3775
    -0.0018 (-0.13%)
     
  • BTC-GBP

    46,414.52
    +1,050.79 (+2.32%)
     
  • CMC Crypto 200

    1,480.21
    +16.85 (+1.15%)
     
  • S&P 500

    4,519.63
    +33.17 (+0.74%)
     
  • DOW

    35,457.31
    +198.70 (+0.56%)
     
  • CRUDE OIL

    82.33
    -0.63 (-0.76%)
     
  • GOLD FUTURES

    1,776.70
    +6.20 (+0.35%)
     
  • NIKKEI 225

    29,255.55
    +40.03 (+0.14%)
     
  • HANG SENG

    26,039.77
    +252.56 (+0.98%)
     
  • DAX

    15,515.83
    +41.36 (+0.27%)
     
  • CAC 40

    6,669.85
    0.00 (0.00%)
     

Coronavirus Disease 2019 (COVID-19) Vaccines and Drugs Contract Pharmaceutical Development and Manufacturing Relationships

·2-min read

Summary This report is the companion to Contract Manufacturing Service Agreements - Rising Manufacturing Opportunities Driven by Pharmaceutical Pipeline Expansion (July 2020).

New York, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Coronavirus Disease 2019 (COVID-19) Vaccines and Drugs Contract Pharmaceutical Development and Manufacturing Relationships" - https://www.reportlinker.com/p06151839/?utm_source=GNW
IT covers contract manufacturing agreements for COVID-19 vaccines and drugs worldwide, across a range of different services and manufacturing scales.

It covers clinical and commercial contracts.As COVID-19 pharmaceuticals are being ordered in billions of doses by numerous governments, the number of contract service agreements secured serves as an indicator of a CMO’s performance.

This report is critical for establishing an understanding of the overall CMO industry as it responds to the challenges and opportunities of the pandemic.

Scope
- This 52-page report gives an important expert quantitative analysis of the contract manufacturing industry’s response to the COVID-19 pandemic. Findings are based on the industry’s most comprehensive databases of the CMO industry (Databases of Contract Service Providers, Drugs, and Deals).
- This analysis is primarily driven by the Deals Database, which is continuously updated and reveals manufacturing relationships for Pharma products and the types of services offered.

The 23 figures and 6 tables throughout the report illustrate major points and trends. This report is required reading for -
- CMO executives who must have deep understanding of the COVID-19 vaccine and drug landscape -- both pipeline and marketed -- to make strategic planning and investment decisions.
- Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
- Investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy
- Overview of contract manufacturing agreements worldwide for COVID-19 pharmaceuticals and the levels of outsourcing associated with different services and drug type
- Detailed view of CDMO performance by contract manufacturing agreement and an assessment of their manufacturing scale
- Manufacturing agreements are assessed by different molecule types, service type, dose form, facility geography, sponsor company types, and CDMO types.
Read the full report: https://www.reportlinker.com/p06151839/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting